Description: <p><b>Carvone</b> — Carvone is a chiral oxygenated monocyclic monoterpene ketone found mainly as enantiomeric forms in spearmint, caraway, dill, and related essential oils. It is best classified as a small-molecule natural product / volatile terpenoid flavor-fragrance compound, commonly abbreviated CRV. The biologically relevant forms are often reported as l-carvone, d-carvone, R-carvone, or S-carvone, but naming conventions are inconsistent across papers, so note the exact enantiomer stated by each source.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of cancer-cell apoptosis through p53, Bad, caspase-3 activation, PARP cleavage, and DNA-damage-associated stress signaling.</li>
<li>Suppression of migration, adhesion, invasion, and metastatic behavior, especially through FAK-related signaling in breast cancer models.</li>
<li>Context-dependent oxidative stress modulation, including ROS increase and DNA damage at cytotoxic in-vitro concentrations.</li>
<li>Inhibition of proliferative survival pathways, including JAK/STAT3 in gastric cancer and p38 MAPK-related signaling in myeloma models.</li>
<li>Cell-cycle disruption, reported as S-phase, G0/G1, or G2/M arrest depending on enantiomer, cancer model, and concentration.</li>
<li>Possible chemopreventive activity in animal skin-carcinogenesis models, but not established as a clinically validated anticancer agent.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Carvone is lipophilic and volatile, with oral, dermal, and inhalational exposure relevance depending on formulation. Human PK/metabolism data exist for ingestion-correlated and topical/percutaneous exposure contexts, but anticancer studies generally use concentrations that are not directly matched to validated systemic anticancer exposure. Essential-oil delivery introduces variability from enantiomer ratio, co-terpenes, oxidation products, and formulation.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Common anticancer in-vitro effects occur at high micromolar to millimolar or microgram-per-millilitre ranges, and breast-cancer IC50 values around the millimolar range have been reported. These levels are likely above ordinary dietary flavor exposure and may exceed practical systemic exposure from food-like intake. Interpretation should therefore be concentration-constrained and formulation-dependent.</p>
<p><b>Clinical evidence status:</b> Preclinical for cancer. Evidence includes cancer cell-line studies, animal chemoprevention/tumor models, and mechanistic studies, but no credible cancer RCTs of carvone as a therapeutic agent were identified. Human studies involving carvone-containing preparations exist for non-cancer indications or mixtures, but they should not be treated as direct anticancer evidence for isolated carvone.</p>
<p><b>Safety / regulatory status:</b> Carvone is listed as a FEMA GRAS flavoring substance with CFR flavor-use reference, but this applies to intended flavor-use exposure, not therapeutic dosing. Major constraints include skin sensitization potential, enantiomer/formulation variability, volatile exposure, and uncertain safety at high supplemental or pharmacologic doses. Fragrance safety assessment data indicate no genotoxic concern under reviewed conditions, but l-carvone is considered a skin sensitizer.</p>
<h3>Carvone Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Apoptosis execution</td>
<td>↑ p53, ↑ Bad, ↑ cleaved caspase-3, ↑ cleaved PARP</td>
<td>Lower sensitivity reported in some normal-cell comparisons</td>
<td>G</td>
<td>Pro-apoptotic cytotoxicity</td>
<td>Most central anticancer mechanism; strongest evidence is in vitro and concentration-dependent.</td>
</tr>
<tr>
<td>2</td>
<td>Migration adhesion invasion</td>
<td>↓ migration, ↓ adhesion, ↓ invasion, ↓ FAK activation</td>
<td>Not well-defined</td>
<td>G</td>
<td>Anti-metastatic phenotype</td>
<td>Mechanistically important for breast cancer models; therapeutic leverage is plausible but not clinically validated.</td>
</tr>
<tr>
<td>3</td>
<td>ROS and DNA damage stress</td>
<td>↑ ROS, ↑ DNA damage markers, ↑ apoptotic stress</td>
<td>Context-dependent antioxidant or cytoprotective effects reported outside cancer</td>
<td>R/G</td>
<td>Stress-mediated apoptosis</td>
<td>ROS appears pro-apoptotic in several cancer contexts; antioxidant effects in non-cancer models make this axis context-dependent.</td>
</tr>
<tr>
<td>4</td>
<td>JAK STAT3 survival signaling</td>
<td>↓ JAK/STAT3 signaling in gastric cancer models</td>
<td>Not well-defined</td>
<td>G</td>
<td>Reduced survival signaling</td>
<td>Promising but model-specific; should not be generalized across all tumor types without direct evidence.</td>
</tr>
<tr>
<td>5</td>
<td>p38 MAPK signaling</td>
<td>↓ p38 MAPK-related signaling in myeloma models</td>
<td>Not well-defined</td>
<td>G</td>
<td>Growth and invasion suppression</td>
<td>Reported in myeloma; secondary/contextual relative to apoptosis and motility effects.</td>
</tr>
<tr>
<td>6</td>
<td>Cell cycle control</td>
<td>↑ arrest at S, G0/G1, or G2/M depending on model</td>
<td>Not well-defined</td>
<td>G</td>
<td>Reduced proliferation</td>
<td>Direction of arrest is inconsistent across cancer systems and enantiomer reports; keep model-specific.</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial apoptosis</td>
<td>↓ mitochondrial membrane potential reported in some models, ↑ caspase-linked apoptosis</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Intrinsic apoptosis support</td>
<td>Relevant when mitochondrial depolarization or ROS-mediated apoptosis is directly measured.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis tumor microenvironment</td>
<td>↓ angiogenesis stimulus in Ehrlich tumor context</td>
<td>Not well-defined</td>
<td>G</td>
<td>Reduced tumor support phenotype</td>
<td>Evidence is less mature than direct cancer-cell apoptosis and migration data.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2 redox adaptation</td>
<td>↔ or uncertain</td>
<td>Possible cytoprotective relevance in oxidative stress models</td>
<td>G</td>
<td>Unresolved redox adaptation</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>High in-vitro concentrations may not map to achievable systemic exposure</td>
<td>Skin sensitization and exposure-route constraints</td>
<td>G</td>
<td>Limits translational confidence</td>
<td>Bioavailability, enantiomer identity, essential-oil composition, and flavor-use versus therapeutic-dose safety are the main constraints.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>